Abstract 5344: High-throughput CRISPR-Cas9 knockout screens identify loss of miRNA1304-5p targeting the RAS/MAPK pathway as a modulator of resistance to ALK inhibitors in high-risk neuroblastoma

Perla Pucci; Liam Lee; Suzanne Turner; Leila Jahangiri; Jamie Matthews; Amos Burke; Patrick Reynolds; Lukas Kenner; Olaf Merkel; Fikret Rifatbegovic; Ji Luo; Peter Ambros; Miaojun Han

doi:10.1158/1538-7445.AM2022-5344

Abstract 5344: High-throughput CRISPR-Cas9 knockout screens identify loss of miRNA1304-5p targeting the RAS/MAPK pathway as a modulator of resistance to ALK inhibitors in high-risk neuroblastoma

Perla Pucci, Liam Lee, Suzanne Turner, Leila Jahangiri, Jamie Matthews, Amos Burke, Patrick Reynolds, Lukas Kenner, Olaf Merkel, Fikret Rifatbegovic, Ji Luo, Peter Ambros, Miaojun Han

Cancer Research UK Clinical Trials Unit

Research output: Contribution to journal › Abstract › peer-review

Original language	English
Article number	5344
Journal	Cancer Research
Volume	82
Issue number	12_Supplement
DOIs	https://doi.org/10.1158/1538-7445.AM2022-5344
Publication status	Published - 15 Jun 2022
Event	AACR Annual Meeting 2022 - New Orleans, United States Duration: 8 Apr 2022 → 13 Apr 2022

Access to Document

10.1158/1538-7445.AM2022-5344

https://aacrjournals.org/cancerres/article/82/12_Supplement/5344/703199/Abstract-5344-High-throughput-CRISPR-Cas9-knockout

Cite this

Pucci, P., Lee, L., Turner, S., Jahangiri, L., Matthews, J., Burke, A., Reynolds, P., Kenner, L., Merkel, O., Rifatbegovic, F., Luo, J., Ambros, P., & Han, M. (2022). Abstract 5344: High-throughput CRISPR-Cas9 knockout screens identify loss of miRNA1304-5p targeting the RAS/MAPK pathway as a modulator of resistance to ALK inhibitors in high-risk neuroblastoma. Cancer Research, 82(12_Supplement), Article 5344. https://doi.org/10.1158/1538-7445.AM2022-5344

@article{2343f87539f14ba18df019ed1b53a620,

title = "Abstract 5344: High-throughput CRISPR-Cas9 knockout screens identify loss of miRNA1304-5p targeting the RAS/MAPK pathway as a modulator of resistance to ALK inhibitors in high-risk neuroblastoma",

author = "Perla Pucci and Liam Lee and Suzanne Turner and Leila Jahangiri and Jamie Matthews and Amos Burke and Patrick Reynolds and Lukas Kenner and Olaf Merkel and Fikret Rifatbegovic and Ji Luo and Peter Ambros and Miaojun Han",

year = "2022",

month = jun,

day = "15",

doi = "10.1158/1538-7445.AM2022-5344",

language = "English",

volume = "82",

journal = "Cancer Research",

issn = "0008-5472",

publisher = "American Association for Cancer Research",

number = "12_Supplement",

note = "AACR Annual Meeting 2022 ; Conference date: 08-04-2022 Through 13-04-2022",

}

Pucci, P, Lee, L, Turner, S, Jahangiri, L, Matthews, J, Burke, A, Reynolds, P, Kenner, L, Merkel, O, Rifatbegovic, F, Luo, J, Ambros, P & Han, M 2022, 'Abstract 5344: High-throughput CRISPR-Cas9 knockout screens identify loss of miRNA1304-5p targeting the RAS/MAPK pathway as a modulator of resistance to ALK inhibitors in high-risk neuroblastoma', Cancer Research, vol. 82, no. 12_Supplement, 5344. https://doi.org/10.1158/1538-7445.AM2022-5344

Abstract 5344: High-throughput CRISPR-Cas9 knockout screens identify loss of miRNA1304-5p targeting the RAS/MAPK pathway as a modulator of resistance to ALK inhibitors in high-risk neuroblastoma. / Pucci, Perla; Lee, Liam; Turner, Suzanne et al.
In: Cancer Research, Vol. 82, No. 12_Supplement, 5344, 15.06.2022.

Research output: Contribution to journal › Abstract › peer-review

TY - JOUR

T1 - Abstract 5344

T2 - AACR Annual Meeting 2022

AU - Pucci, Perla

AU - Lee, Liam

AU - Turner, Suzanne

AU - Jahangiri, Leila

AU - Matthews, Jamie

AU - Burke, Amos

AU - Reynolds, Patrick

AU - Kenner, Lukas

AU - Merkel, Olaf

AU - Rifatbegovic, Fikret

AU - Luo, Ji

AU - Ambros, Peter

AU - Han, Miaojun

PY - 2022/6/15

Y1 - 2022/6/15

U2 - 10.1158/1538-7445.AM2022-5344

DO - 10.1158/1538-7445.AM2022-5344

M3 - Abstract

SN - 0008-5472

VL - 82

JO - Cancer Research

JF - Cancer Research

IS - 12_Supplement

M1 - 5344

Y2 - 8 April 2022 through 13 April 2022

ER -